Thursday, 1 October 2015

Genentech have announced positive results from a phase III study of ocrelizumab in primary progressive MS

Source Pharmiweb.com

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from a pivotal Phase III study that evaluated the investigational medicine ocrelizumab in people with primary progressive multiple sclerosis (PPMS).  Read on.